Stanford University spinoff NuMedii has landed a deal with Aptalis Pharma to apply its predictive “Big Data” technology. The companies aim to hunt down and advance drugs to combat gastrointestinal ailments and cystic fibrosis, which are two areas of focus at Aptalis. The deal boosts the commercial credentials of NuMedii, building on the startup’s role in a pair of papers last year that showed how its computational method could quickly pair approved and generic drugs with new potential uses against diseases.
NuMedii’s predictive Big Data discovery technology and its preclinical de-risking expertise are a great fit with Aptalis’ proven capabilities in formulation, clinical development and commercialization of new therapeutics,” said Gini Deshpande, PhD, NuMedii’s CEO and co-founder.
In an interview, Deshpande said that the company is hunting for additional deals with specialty pharma groups as well as partnerships that would enable the company to identify new uses for “shelved” compounds no longer in clinical development. Read the Full Story.